NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $30.15 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.16 +0.01 (+0.03%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harmony Biosciences Stock (NASDAQ:HRMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harmony Biosciences alerts:Sign Up Key Stats Today's Range$29.96▼$30.8150-Day Range$26.54▼$32.7852-Week Range$25.52▼$40.87Volume431,487 shsAverage Volume750,644 shsMarket Capitalization$1.75 billionP/E Ratio12.16Dividend YieldN/APrice Target$40.89Consensus RatingHold Company Overview Harmony Biosciences Holdings, Inc. is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments. The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. WAKIX was granted approval in August 2019 following pivotal Phase III clinical trials demonstrating its efficacy and tolerability profile. Harmony Biosciences has established a commercial infrastructure across the United States to support patient access, education, and ongoing research into expanded indications. In addition to its marketed therapy, Harmony Biosciences maintains a clinical development program to evaluate pitolisant in other sleep disorders and cognitive conditions, leveraging its expertise in histaminergic modulation. The company collaborates with academic institutions, patient advocacy groups, and specialty pharmacies to facilitate real‐world data collection and to enhance support services for patients and healthcare providers. Harmony continues to explore strategic partnerships and licensing arrangements to extend its reach into international markets. Harmony Biosciences is led by President and Chief Executive Officer Joseph P. Woody, whose leadership team brings together experience in specialty pharmaceuticals, regulatory affairs, and commercial operations. With a focus on patient‐centric innovation and long‐term value creation, Harmony Biosciences aims to address unmet needs in rare disease communities while expanding its pipeline and geographic footprint.AI Generated. May Contain Errors. Read More Harmony Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreHRMY MarketRank™: Harmony Biosciences scored higher than 90% of companies evaluated by MarketBeat, and ranked 42nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingHarmony Biosciences has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialHarmony Biosciences has a consensus price target of $40.89, representing about 35.6% upside from its current price of $30.15.Amount of Analyst CoverageHarmony Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Harmony Biosciences' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth13.75% Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 13.75% in the coming year, from $3.20 to $3.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 12.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 12.16, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.01.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.20. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.40% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 5.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.67 News SentimentHarmony Biosciences has a news sentiment score of -0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Harmony Biosciences this week, compared to 5 articles on an average week.Search Interest7 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.00% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRMY Stock News HeadlinesHarmony Biosciences Holdings Inc.May 17, 2026 | barrons.comInvestors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings QualityMay 14, 2026 | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 25 at 1:00 AM | Brownstone Research (Ad)Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic HypersomniaMay 14, 2026 | businesswire.comHarmony Biosciences Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 13, 2026 | seekingalpha.comEarnings Miss: Harmony Biosciences Holdings, Inc. Missed EPS By 21% And Analysts Are Revising Their ForecastsMay 11, 2026 | finance.yahoo.comHarmony Biosciences Holdings (HRMY) Valuation After Q1 2026 Earnings Miss And Profitability ConcernsMay 9, 2026 | finance.yahoo.comShould Harmony Biosciences’ Softer Q1 2026 Earnings and Upbeat Forecasts Require Action From HRMY Investors?May 8, 2026 | finance.yahoo.comSee More Headlines HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $37.42 at the start of the year. Since then, HRMY shares have decreased by 19.4% and is now trading at $30.15. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its quarterly earnings results on Thursday, May, 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by $0.21. The business's revenue for the quarter was up 16.6% compared to the same quarter last year. Read the conference call transcript. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $115 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 5,348,837 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Top institutional shareholders of Harmony Biosciences include Dimensional Fund Advisors LP (3.59%), SG Americas Securities LLC (3.49%), Arrowstreet Capital Limited Partnership (2.39%) and Renaissance Technologies LLC (1.86%). Insiders that own company stock include Sandip Kapadia, Jeffrey M Dayno and Jeffrey Dierks. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/07/2026Today5/25/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 HRMY's financial health is in the Red zone, according to TradeSmith. HRMY has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year Founded2017Price Target and Rating Average Price Target for Harmony Biosciences$40.89 High Price Target$62.00 Low Price Target$28.00 Potential Upside/Downside+35.6%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$2.48 Trailing P/E Ratio12.16 Forward P/E Ratio9.42 P/E Growth0.2Net Income$158.69 million Net Margins16.20% Pretax Margin21.97% Return on Equity17.19% Return on Assets11.99% Debt Debt-to-Equity Ratio0.15 Current Ratio3.58 Quick Ratio3.56 Sales & Book Value Annual Sales$868.45 million Price / Sales2.01 Cash Flow$3.18 per share Price / Cash Flow9.48 Book Value$15.73 per share Price / Book1.92Miscellaneous Outstanding Shares57,890,000Free Float51,525,000Market Cap$1.75 billion OptionableOptionable Beta0.97 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:HRMY) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
